	ACTIVE TRIALS- METHODIST DALLAS LIVER INSTITUTE	
Protocol ID	Study Title	PI
RNHE2041	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging,	Barnes
	Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble	
	Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt	
	Hepatic Encephalopathy (OHE)	
CC-90001-NASH-	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter,	Mantry
001	Dose-Finding Study to Evaluate the Efficacy and Safety of CC-90001 in	
	Subjects with Non-alcoholic Steatohepatitis and Stage 3 or Stage 4 Liver	
	Fibrosis	
505-315-1	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III	Mantry
	Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with	-
	Nonalcoholic Steatohepatitis and fibrosis	
GS-US-428-4194	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study	Mantry
	Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Non-	/
	Cirrhotic Subjects with Primary Sclerosing Cholangitis	
GS-US-454-5533	A Proof of Concept, Open-Label Study Evaluating the Safety,	Mantry
	Tolerability, and Efficacy of Monotherapy and Combination Regimens in	ivianci y
	Subjects with Nonalcoholic Steatohepatitis	
GS-US-428-5443	A Proof-of-Concept, Open-Label Study Evaluating the Safety and	Mantry
05 05 420 5445	Tolerability of Cilofexor in Subjects with Primary Sclerosing Cholangitis	ivianci y
	and Compensated Cirrhosis	
HQ-US-SHUNT-	The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large	Mantry
1801	Esophageal Varices: The Shunt-V	ivianci y
747-304	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter	Mantry
717 301	Study to Evaluate the Efficacy and Safety of Obeticholic-Acid in Subjects	ivianci y
	with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	
747-302	A Phase 4, Double-Blind, Randomized , Placebo-Controlled, Multicenter	Mantry
717 302	Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in	ivianci y
	Subjects with Primary Biliary Cholangitis	
2018-01	Prospective Clinical Trial to Detect Liver Cancer through Quantification	Mantry
2010 01	of cfDNA Methylation in Blood Samples (CLiMB)	ivianci y
ECH-NASH-001	A Study to Evaluate the Degree of Steatosis in Subjects with any Feature	Mantry
Len NASH 001	of the Metabolic Syndrome in Primary Care or Endocrine Clinics for	ivianci y
	Non-Alcoholic Fatty Liver Disease Utilizing Vibration Controlled	
	Transient Elastography and Controlled Attenuation Parameter	
TARGET-HCC	A 5-year Longitudinal Observational Study of the Natural History and	Mantry
TANGET-TICC	Management of Patients with Hepato-cellular Carcinoma	ivialiti y
STELLARIS: 3152-	STELLARIS: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-	Mantry
301-002	Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc in	ivialiti y
501-002	Adult Subjects with Nonalcoholic Steatohepatitis and Liver Fibrosis	
747-401	A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study	Mehta
747-401	Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in	Wenta
	Patients with Primary Biliary Cholangitis and Moderate to Severe	
	Hepatic Impairment	

ACTIVE TRIALS- METHODIST DALLAS LIVER INSTITUTE

CVAY736B2201	A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER)	Nazario
CB8025-31735	A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis and an inadequate response to or an intolerance to ursodeoxy-cholic acid	Pagadala
MGL-3196-11	A Phase 3/4, Multinational, Double-Blind, Randomized, Placebo- Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis	Pagadala